2349 related articles for article (PubMed ID: 33216381)
1. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
2. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.
Raj K; Kaur K; Gupta GD; Singh S
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1383-1402. PubMed ID: 33961065
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
4. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
Front Immunol; 2020; 11():569760. PubMed ID: 33362758
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
7. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine: where are we now and where should we go?
Soleimanpour S; Yaghoubi A
Expert Rev Vaccines; 2021 Jan; 20(1):23-44. PubMed ID: 33435774
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Infection: Targeting Possibilities for Treatment.
Haider T; Gour V; Pandey V; Kanwar IL; Tiwari R; Vishwakarma M; Bakshi AK; Sarkar A; Yadav R; Soni S; Soni V
Crit Rev Ther Drug Carrier Syst; 2021; 38(3):75-115. PubMed ID: 34348019
[TBL] [Abstract][Full Text] [Related]
12. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
13. Combining Antivirals and Immunomodulators to Fight COVID-19.
Feuillet V; Canard B; Trautmann A
Trends Immunol; 2021 Jan; 42(1):31-44. PubMed ID: 33281063
[TBL] [Abstract][Full Text] [Related]
14. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
Bilal M; Iqbal HMN
Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
[TBL] [Abstract][Full Text] [Related]
16. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
[TBL] [Abstract][Full Text] [Related]
17. Peptide and peptide-based inhibitors of SARS-CoV-2 entry.
Schütz D; Ruiz-Blanco YB; Münch J; Kirchhoff F; Sanchez-Garcia E; Müller JA
Adv Drug Deliv Rev; 2020 Dec; 167():47-65. PubMed ID: 33189768
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic.
Ray SK; Mukherjee S
Recent Pat Antiinfect Drug Discov; 2020; 15(2):89-103. PubMed ID: 32957894
[TBL] [Abstract][Full Text] [Related]
19. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective.
Lee C; Choi WJ
Arch Pharm Res; 2021 Jan; 44(1):99-116. PubMed ID: 33398692
[TBL] [Abstract][Full Text] [Related]
20. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
